Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Bevacizumab for the treatment of pediatric retinal and choroidal diseases.
[coats disease]
To
determine
the
efficacy
of
off-label
intravitreal
bevacizumab
(
IVB
)
for
the
treatment
of
pediatric
retinal
and
choroidal
vascular
diseases
.
Retrospective
,
non-comparative
,
open
-label
,
interventional
,
consecutive
case
series
of
all
patients
younger
than
18
years
treated
with
off-label
IVB
at
a
single
center
from
January
1
,
2005
,
to
January
1
,
2008
.
Primary
outcome
measures
with
best-corrected
visual
acuity
by
age-appropriate
testing
and
central
macular
thickness
by
time-domain
optical
coherence
tomography
.
Thirty
-
five
eyes
of
33
patients
were
treated
with
IVB
alone
or
in
combination
with
other
treatments
for
choroidal
neovascularization
,
Coats
'
disease
,
familial
exudative
vitreoretinopathy
,
and
various
other
indications
.
IVB
was
used
in
24
eyes
to
reduce
excess
retinal
fluid
and
exudation
.
Mean
Snellen
visual
acuity
improved
from
20
/
170
at
baseline
to
20
/
100
at
1
month
(
P
=
.
006
)
,
20
/
80
at
3
months
(
P
=
.
006
)
,
and
20
/
50
at
6
months
(
P
=
.
023
)
.
Central
macular
thickness
improved
from
356
μm
at
baseline
to
287
μm
at
6
months
(
P
=
.
028
)
.
IVB
was
used
in
11
eyes
to
control
peripheral
retinal
neovascularization
and
iris
rubeosis
.
Although
IVB
reduced
vascular
engorgement
,
it
did
not
prevent
the
progression
of
preretinal
tractional
forces
.
Mean
visual
acuity
was
maintained
at
each
time
point
.
No
systemic
or
ocular
adverse
events
were
directly
attributable
to
IVB
in
any
patient
.
IVB
reduced
vascular
leakage
and
temporarily
regressed
pathologic
neovascularization
of
the
choroid
,
retina
,
and
iris
in
this
series
of
pediatric
patients
.
Further
prospective
studies
are
warranted
.
Diseases
Validation
Diseases presenting
"various other indications"
symptom
coats disease
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom